Menu

Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research

The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.

Jan 7, 2018
Jim Daley

ISTOCK, NO_LIMIT_PICTURES

US pharmaceutical corporation Pfizer announced plans this week to abandon research of new drugs to treat Alzheimer’s and Parkinson’s diseases. The decision will result in about 300 layoffs in the company’s neuroscience discovery and early development programs, which are located in Massachusetts and Connecticut, according to a statement emailed to journalists.

“We have made the decision to end our neuroscience discovery and early development efforts and reallocate funding to those areas where we have strong scientific leadership and that will allow us to provide the greatest impact for patients,” the company says in the statement (via Reuters).

According to Reuters, Pfizer will continue to develop some drugs in its neuroscience pipeline, such as tanezumab, for osteoarthritis-related joint pain and Lyrica (pregabalin), which is used to treat nerve pain associated with fibromyalgia and diabetes. The company also plans to initiate a new venture fund for neuroscience research.

Pfizer is currently part of the Dementia Discovery Fund, which was launched in 2015 to develop new Alzheimer’s treatments. However, some of its attempts to develop new drugs for the conditions have failed. According to Reuters, Pfizer’s partnership with Johnson & Johnson to develop bapineuzumab, a drug to treat patients with mild to moderate Alzheimer’s, ended in disappointment in 2012 after a second round of clinical trials was unsuccessful.

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Best Practices: Calculating Cell Confluency
Best Practices: Calculating Cell Confluency
In this white paper, learn how to use a cell imager system to directly and accurately capture and calculate cell confluency!
LabTwin's AI-powered Digital Assistant Now Talks Back and Connects Data Sources in the Lab with New Open API
LabTwin's AI-powered Digital Assistant Now Talks Back and Connects Data Sources in the Lab with New Open API
LabTwin GmbH, the world's first voice and AI-powered digital lab assistant, today announced its new open API that will connect scientists with data sources both inside and outside of the lab. 
BCG Digital Ventures and Sartorius Help Launch the World's First Voice-powered Digital Assistant for Scientists
BCG Digital Ventures and Sartorius Help Launch the World's First Voice-powered Digital Assistant for Scientists
LabTwin GmbH, an independent company backed by Boston Consulting Group Digital Ventures (BCG Digital Ventures) and leading biopharma supplier, Sartorius, today announced the launch of the world's first voice and AI-powered digital lab assistant.
Understanding Transcriptomic or Proteomic Datasets to Reveal Biological Mechanisms
Understanding Transcriptomic or Proteomic Datasets to Reveal Biological Mechanisms
When analyzing large transcriptomics or proteomics datasets, we want to understand whether the phenomenon is unusual or commonplace and whether there are informative similarities to other areas of biology. To learn more about how Ingenuity Pathway Analysis (IPA®) and Analysis Match can help, download this white paper from QIAGEN!